Analysis of the CΥP2D6 gene in relation to dextromethorphan O- demethylation capacity in a Japanese population

Clinical Pharmacology and Therapeutics

Volumn 65, Issue 5, 1999, Pages 570-575

  Tateishi, Tomonori ^a,b,c   Chida, Michihiro ^a,b,c   Ariyoshi, Noritaka ^a,b,c   Mizorogi, Yoshihiro ^a,b,c   Kamataki, Tetsuya ^a,b,c   Kobayashi, Shinichi ^a,b,c  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Division of Pharmacobio dynamics   (Japan)

^c Clinical Pharmacology Center   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DEBRISOQUINE 4 HYDROXYLASE; DEXTROMETHORPHAN; LEVALLORPHAN; O DEMETHYLASE; CYTOCHROME P450; CYTOCHROME P450 2D6; DEXTROMETHORPHAN O DEMETHYLASE; DEXTROMETHORPHAN O-DEMETHYLASE;

ADULT; ARTICLE; DRUG METABOLISM; ENZYME ACTIVITY; GENE AMPLIFICATION; GENE FREQUENCY; GENETIC ANALYSIS; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; JAPAN; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; ALLELE; ASIAN; GENETICS; METABOLISM; METHYLATION; REFERENCE VALUE;

ADULT; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DEXTROMETHORPHAN; GENOTYPE; HUMANS; JAPAN; MALE; METHYLATION; OXIDOREDUCTASES, O-DEMETHYLATING; PHENOTYPE; POLYMERASE CHAIN REACTION; REFERENCE VALUES;

EID: 0032586732     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)70077-9     Document Type: Article

References (24)

1. 1. Werner K. Interethnic variation of drug metabolism. Trends Pharmacol Sci 1991;12:102-7.
2. 2. Bertilsson L. Geographical/interracial differences in polymorphic oxidation: current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995;29:192-209.
3. 3. Guengerich FP. Human cytochrome P450 enzymes. In: Oritiz de Montellano PR, editor. Cytochrome P450. New York: Plenum Press; 1995. p. 473-535.
4. 4. Gonzalez FJ, Meyer UA. Molecular genetics of the debrisoquin-sparteine polymorphism. Clin Pharmacol Ther 1991;50:233-8.
5. 5. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996;6:193-201.
6. 6. Broly F, Gaedik A, Helm M, Eichelbaum M, Morike K, Meyer UA. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 1991;10:545-8.
7. 7. Evans WE, Relling MW, Rahman A, McLeod H, Scott E, Lin JS. Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. J Clin Invest 1993;91:2150-4.
8. 8. Lou YC, Ying L, Bertilsson L, Sjöqvist F. Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet 1987;2:852-3.
9. 9. Horai Y, Ishizaki T, Ishikawa K. Metoprolol oxidation in a Japanese population: evidence for only one poor metabolizer among 262 subjects. Br J Clin Pharmacol 1988; 26:807-8.
10. 10. Dahl ML, Yue QY, Roh HK, Johansson I, Säwe J, Sjöqvist F, et al. Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics 1995;5:159-64.
11. 11. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 2D-locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993;90:11825-9.
12. 12. Dahl ML, Johansson L, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995;274:516-20.
13. 13. Agúndez JAG, Ledesma MC, Ladero JM, Benitez J. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995;57:265-9.
14. 14. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996;278:441-6.
15. 15. Horai Y, Nakano M, Ishizaki T, Ishikawa K, Zhou HH, Zhou B J, et al. Metoprolol and mephenytoin oxidation polymorphism in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989;46: 198-207.
16. 16. Wang SL, Huang JD, Lai MD, Liu BH, Lai ML. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 1993;53:410-8.
17. 17. Schmid B, Bircher J, Preisig R, Küpfer A. Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquine hydroxylation. Clin Pharmacol Ther 1985;38:618-24.
18. 18. Bartoletti RA, Belpaire FM, Rosseel MT. High performance liquid chromatography determination of dextromethorphan and its metabolites in urine using solid-phase extraction. J Pharm Biomed Anal 1996;14:1281-6.
19. 19. Yokoi T, Kosaka Y, Chida M, Chiba K, Nakamura H, Ishizaki T, et al. A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype. Pharmacogenetics 1996;6:395-401.
20. 20. Heim M, Meyer UA. Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 1990;336:529-32.
21. 21. Johansson I, Lundqvist E, Dahl ML, Ingelman-Sundberg M. PCR-based genotyping for duplicated deleted CYP2D6 genes. Pharmacogenetics 1996;6:351-6.
22. 22. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 gene present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994;46:452-9.
23. 23. Agúndez JAG, Martinez C, Ledesma MC, Ladona MG, Ladero JM, Benitez J. Genetic basis for differences in debrisoquin polymorphism between a Spanish and other white populations. Clin Pharmacol Ther 1994;55:412-7.
24. 24. Armstrong M, Fairbrother K, Idle JR, Daly AK. The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphism in a European population. Pharmacogenetics 1994;4:73-81.